Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Global Blood Therapeutics stock
Learn how to easily invest in Global Blood Therapeutics stock.
Global Blood Therapeutics Inc is a biotechnology business based in the US. Global Blood Therapeutics shares (GBT) are listed on the NASDAQ and all prices are listed in US Dollars. Global Blood Therapeutics employs 457 staff and has a trailing 12-month revenue of around $234.9 million.
How to buy shares in Global Blood Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – GBT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Global Blood Therapeutics stock price (NASDAQ: GBT)Use our graph to track the performance of GBT stocks over time.
Global Blood Therapeutics shares at a glance
|Latest market close||$67.97|
|52-week range||$21.65 - $73.02|
|50-day moving average||$54.31|
|200-day moving average||$35.82|
|Wall St. target price||$66.63|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-4.86|
Buy Global Blood Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Global Blood Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Global Blood Therapeutics price performance over time
|1 week (2022-09-16)||0.52%|
|1 month (2022-08-24)||0.80%|
|3 months (2022-06-24)||113.81%|
|6 months (2022-03-23)||102.53%|
|1 year (2021-09-24)||165.82%|
|2 years (2020-09-24)||27.40%|
|3 years (2019-09-24)||24.83%|
|5 years (2017-09-22)||138.49%|
Global Blood Therapeutics financials
|Revenue TTM||$234.9 million|
|Gross profit TTM||$191.4 million|
|Return on assets TTM||-25.18%|
|Return on equity TTM||-148.56%|
|Market capitalisation||$4.6 billion|
TTM: trailing 12 months
Global Blood Therapeutics share dividends
We're not expecting Global Blood Therapeutics to pay a dividend over the next 12 months.
Global Blood Therapeutics share price volatility
Over the last 12 months, Global Blood Therapeutics's shares have ranged in value from as little as $21.65 up to $73.02. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Global Blood Therapeutics's is 0.4634. This would suggest that Global Blood Therapeutics's shares are less volatile than average (for this exchange).
Global Blood Therapeutics overview
Global Blood Therapeutics, Inc. , a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.
Global Blood Therapeutics in the news
GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022
GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022
GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics Conference
Frequently asked questionsWhat percentage of Global Blood Therapeutics is owned by insiders or institutions?
Currently 2.421% of Global Blood Therapeutics shares are held by insiders and 112.145% by institutions. How many people work for Global Blood Therapeutics?
Latest data suggests 457 work at Global Blood Therapeutics. When does the fiscal year end for Global Blood Therapeutics?
Global Blood Therapeutics's fiscal year ends in December. Where is Global Blood Therapeutics based?
Global Blood Therapeutics's address is: 181 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 What is Global Blood Therapeutics's ISIN number?
Global Blood Therapeutics's international securities identification number is: US37890U1088 What is Global Blood Therapeutics's CUSIP number?
Global Blood Therapeutics's Committee on Uniform Securities Identification Procedures number is: 37890U108
More guides on Finder
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.
Ask an Expert